LABORATORY SCIENCES. Attenuation of Iodine 125 Radiation With Vitreous Substitutes in the Treatment of Uveal Melanoma
|
|
- Leon Grant
- 5 years ago
- Views:
Transcription
1 LABORATORY SCIENCES Attenuation of Iodine 125 Radiation With Vitreous Substitutes in the Treatment of Uveal Melanoma Scott C. N. Oliver, MD; Min Y. Leu, PhD; John J. DeMarco, PhD; Philip E. Chow, MS; Steve P. Lee, MD, PhD; Tara A. McCannel, MD, PhD Objective: To demonstrate attenuation of radiation from iodine 125 ( 125 I) to intraocular structures using liquid vitreous substitutes. Methods: Four candidate vitreous substitutes were tested for attenuation using empirical measurement and theoretical calculation. In vitro and ex vivo cadaveric dosimetry measurements were obtained with lithium fluoride thermoluminescent dosimeters to demonstrate the attenuation effect of vitreous substitution during 125 I simulated plaque brachytherapy. Theoretical dosimetry calculations were based on Monte Carlo simulation. Results: In a cylindrical phantom at a 17-mm depth, liquid vitreous substitutes as compared with saline showed significant reduction of radiation penetration (48% for 1000-centistoke [cst] silicone oil [polydimethyl-nsiloxane], 47% for 5000-cSt silicone oil [polydimethyln-siloxane], 40% for heavy oil [perfluorohexyloctane/ polydimethyl-n-siloxane], and 35% for perfluorocarbon liquid [perfluoro-n-octane]). Human cadaveric ex vivo measurements demonstrated a 1000-cSt silicone oil to saline dose ratio of 35%, 52%, 55%, and 48% at arc lengths of 7.6, 10.6, 22.3, and 28.6 mm from the plaque edge, respectively, along the surface of the globe. Monte Carlo simulation of a human globe projected attenuation as high as 57% using 1000-cSt silicone oil. Conclusions: Intraocular vitreous substitutes including silicone oil, heavy oil, and perfluorocarbon liquid attenuate the radiation dose from 125 I. Cadaveric ex vivo measurements and Monte Carlo simulation both demonstrate radiation attenuation using 1000-cSt silicone oil at distances corresponding to vital ocular structures. Clinical Relevance: Attenuation of radiation with silicone oil endotamponade in the treatment of uveal melanoma may significantly reduce radiation-induced injury to vital ocular structures. Arch Ophthalmol. 2010;128(7): Author Affiliations: Department of Ophthalmology, Jules Stein Eye Institute (Drs Oliver and McCannel), Department of Radiation Oncology (Drs Leu, DeMarco, and Lee and Mr Chow), and Jonsson Comprehensive Cancer Center (Dr McCannel), University of California, Los Angeles. Dr Oliver is now with the Rocky Mountain Lions Eye Institute, University of Colorado Denver, Aurora. MELANOMA ARISING from the choroid and ciliary body is the most common primary intraocular cancer. 1 The Collaborative Ocular Melanoma Study (COMS) randomized clinical trial of iodine 125 ( 125 I) brachytherapy vs enucleation for medium-sized choroidal melanoma ( mm in thickness and 16 mm in diameter) showed that for patients who met the eligibility criteria, there was no statistically significant difference in all-cause mortality between 125 I brachytherapy and enucleation 5, 10, and 12 years following treatment. 2-4 The COMS supported the use of globe-conserving 125 I brachytherapy. Following brachytherapy, however, visual acuity in the treated eye generally declined at a rate of approximately 2 lines of visual acuity per year and nearly 45% of patients lost ambulatory vision (visual acuity 20/200) in the treated eye by 3 years. 5 Adverse effects of plaque brachytherapy include cataract, radiationassociated proliferative retinopathy, maculopathy, and papillopathy. Radiation maculopathy, which may result in decreased central vision, cystoid macular edema, macular ischemia, and chorioretinal atrophy, was reported in other series to occur in 18% to 43% of treated eyes within 5 years after brachytherapy. 6,7 In the COMS, photographic and angiographic evidence of radiation-associated macular pathology was as high as 75% at 5 years. 8 Typical onset occurred 18 to 24 months following treatment. 6,9 Primary risk factors for radiation papillopathy and maculopathy include total radiation dose to the affected structures, proximity of the tu- 888
2 125 I plaque Tumor 125I seed Thin plastic film Thin-walled plastic container Radiation-attenuating liquid is placed in the vitreous space 17 mm Solution TLD chips Optic nerve mor to the affected structures, and systemic conditions such as diabetes mellitus. 7,10,11 No treatment for radiation maculopathy or papillopathy has been proven to be effective in a randomized clinical trial. The target dose to the tumor apex in the COMS was 85 Gy (to convert to rad, multiply by 100). 12,13 Current plaque design methods are based on the parameters of tumor base diameter and tumor height. Collateral injury to the optic nerve and macula has been retrospectively observed to occur at threshold doses of approximately 35 Gy and 21 Gy to each structure, respectively. 14,15 The maximum tolerance dose to the optic nerve for blindness is 50 Gy based on the Radiation Therapy Oncology Group recommendation of 1.8 Gy per fraction, 5 fractions per week. 16 Using the COMS protocol, plaque design is not altered even if collateral injury is anticipated to occur. Radiation injury to vital structures may be shielded with the use of materials such as lead that have a higher effective atomic number and density than tissue. However, solid metals are not amenable to use within the eye. Based on these considerations, we present a new method to reduce radiation penetration through the eye from plaque brachytherapy. This study demonstrates the ability of 4 liquids commonly used in vitreoretinal surgery to attenuate gamma radiation from 125 I. In the future, placement of one of these liquids in the eye at the time of plaque brachytherapy may significantly reduce collateral injury to adjacent structures in vivo (Figure 1). METHODS Field of radiation Figure 1. Schematic drawing of vitreous substitution to shield vital intraocular structures during iodine 125 ( 125 I) brachytherapy for uveal melanoma. Four candidate vitreous substitutes were tested for attenuation effect using both empirical measurement and theoretic calculation methods. The measurements were conducted using individually calibrated high-sensitivity lithium fluoride thermoluminescent dosimeters (TLDs) (TLD-100H; Thermo Fisher Scientific, Inc, Waltham, Massachusetts). Dosimetry calculations based on a Monte Carlo code were also performed to verify the measured attenuation effect. In vitro and ex vivo dosimetry was studied to simulate the attenuation effect of vitreous substitution during 125 I plaque brachytherapy for the treatment of uveal melanoma. Figure 2. In vitro thermoluminescent dosimeter (TLD) measurement of the radiation attenuation by vitreous substitutes. An iodine 125 ( 125 I) source (top) was placed over a cup containing 9.0 ml of each substance. Four TLD chips were placed under the cup. RADIATION ATTENUATION EFFECT OF 4 CANDIDATE VITREOUS SUBSTITUTES The radiation attenuation effect was assessed for 4 substances commonly used in vitreoretinal surgical procedures. They are the following: (1) 1000-centistoke (cst) silicone oil (SILIKON 1000 silicone oil; Alcon Laboratories, Inc, Fort Worth, Texas); (2) 5000-cSt silicone oil (ADATO SIL-OL 5000; Bausch & Lomb, Inc, Rochester, New York); (3) heavy oil (Densiron 68; Geuder AG, Heidelberg, Germany); and (4) perfluorocarbon liquid (perfluoro-n-octane) (Perfluoron; Alcon Laboratories, Inc). A sodium chloride saline solution was used as a control. Both cst and 5000-cSt silicone oils are purified polymeric polydimethyln-siloxane, approved by the US Food and Drug Administration for long-term retinal endotamponade. The 2 oils differ only in polymer length and thus viscosity; 1000-cSt silicone oil is less viscous than 5000-cSt silicone oil. Densiron 68 heavy oil is a blend of polydimethyl-n-siloxane and perfluorohexyloctane that is denser than water. It is not approved by the US Food and Drug Administration but is available in Europe for retinal endotamponade. Perfluoro-n-octane is a US Food and Drug Administration approved heavy liquid used in vitreoretinal surgery. TLD Measurement High-sensitivity lithium fluoride TLDs, mm in dimension, were calibrated and assigned individual chip factors to compensate for the difference in individual chip responses. The estimated SD of the TLD readings for the dose range used in this study is 2.5%. The corrected TLD readings were further converted to radiation doses using a third-order polynomial regression formula, which has an adjusted r 2 greater than for the dose range of interest. A thin plastic cylindrical cup, 26 mm in diameter and 20 mm in height, was filled with 9.0 ml, or 17 mm in height, of each candidate substance. A brachytherapy 125 I source (MED3631-A/M; North American Scientific Medical, Chatsworth, California) was placed above the cylinder, and 4 TLD-100H chips (Figure 2) were placed on the bottom. The whole system was put on a plastic slab to simulate radiation backscatter in a human body. The TLD chips were irradiated for approximately 25 hours for each attenuating solution. The measured doses were further corrected for source decay and collecting time difference. Monte Carlo Calculation Theoretical calculations of the attenuated radiation dose were performed using a general-purpose Monte Carlo code 889
3 125 I plaque 4.15 mm 3.4 mm 3.0 mm Optic nerve A B C 11.7 mm D 6.3 mm (MCNPX_26C). This standard modeling package, capable of simulating coupled photon-electron interactions with media in a 3-dimensional heterogeneous geometry system, has recently been studied by our group and found accurate in predicting dose distributions in tissue from 125 I brachytherapy seeds. The calculated radial dose function in water of an 125 I source from this module showed good agreement with the consensus data of the American Association of Physicists in Medicine Task Group No and the Monte Carlo calculations of Rivard. 18 The discrepancy was within ±5% for radial distance less than 3.0 cm and gradually increased to ±14% at a distance of 7.0 cm. The TLD measurement geometry described earlier was also simulated using Monte Carlo calculations to verify the measured attenuation. Monte Carlo simulation requires estimation of the effective atomic number of each vitreous substitute. The 1000-cSt silicone oil is a polydimethyl-n-siloxane (C 8 H 24 N 3 O 2 ) polymer with a repeating middle chain. The cst silicone oil has a similar composition except for a slightly higher viscosity due to the longer average chain length. The exact average chain length for each substance is protected by trade secret. However, a comparison using the Monte Carlo model of polydimethyl-n-siloxane effective atomic numbers of 1 and 10 repeating middle chains found minimal difference in calculated attenuation effect. The Monte Carlo calculation was not performed for Densiron 68 heavy oil as the proportional mixture of polydimethyl-n-siloxane and perfluorohexyloctane is protected by trade secret. The effective atomic number of perfluoro-n-octane was calculated based on the published company data sheet. ATTENUATION EFFECT TO CRITICAL OCULAR STRUCTURES Ex Vivo Testing Cornea Figure 3. Dosimetry points in a cadaveric human eye model of vitreous substitution for radiation blockade. A indicates macula; B, proximal margin of optic nerve; C, distal margin of optic nerve; D, equator; and E, ora serrata. 125 I indicates iodine 125. Arc distances are in millimeters based on standard dimensions from the Collaborative Ocular Melanoma Study. 19 E The University of California, Los Angeles eye plaque design is similar to a COMS-style plaque but uses a custom-fabricated gold shield and a spherically symmetric seed design. The brachytherapy seeds are glued onto the inner surface of the gold plaque, and the plaque opening is filled with a tissue-equivalent sealant material. The 1000-cSt silicone oil, hereafter referred to as silicone oil, was selected for further testing because this substance exhibited the maximum attenuation effect. To simulate the effect of vitreous replacement with silicone oil, a cadaveric experiment using 3 donor globes was performed. In each experiment, calibrated TLD chips were wrapped in a single layer of impermeable polyvinyl chloride film and placed against the globe at specified locations corresponding to vital ocular structures (Figure 3). An 125 I plaque was then affixed to the globe in a horizontal plane 7.6 mm temporal to the posterior optic nerve margin. After a measured period, the chips and plaque were removed and vitreous was excised using either a 3-port pars plana vitrectomy or a limbal incision with manual scissors vitrectomy. Silicone oil was then infused to fill the eye. All wounds were sutured closed. Newly calibrated TLD chips were placed at identical locations of the prior measurement sites. The same radioactive plaque was sutured to the previous location for a measured period. The radiation dose rates were determined after compensating for source decay and duration of TLD placement. The dose ratio at each site before and after vitreous substitution was calculated. The results are summarized in Table 1. Monte Carlo Modeling A 15-seed eye plaque, 16 mm in diameter, was simulated using a Monte Carlo model to account for the intrinsic seed properties, the physical seed geometry, and the gold plaque. The calculation was based on a spherically symmetric globe with an equatorial diameter equal to 24 mm and filled with water or replacement silicone oil. The sclera was modeled as a 1-mmthick, separate spherical layer surrounding the globe. The dose ratios at the same vital structures were estimated as earlier. RESULTS The measured and calculated penetration factors of the 4 candidate substances compared with those of saline are listed in Table 2. The most robust attenuation effect was from 1000-cSt silicone oil (48%), followed by 5000-cSt silicone oil (47%), heavy oil (40%), and perfluorocarbon liquid (35%). The attenuation results of Monte Carlo calculations ranged from 42% to 52% and were within 6% to 11% agreement of measured results (Table 2 and Figure 4). Ex vivo testing demonstrated attenuation of radiation to structures opposite the plaque (Table 1). With a plaque placed 7.6 mm temporal to the optic nerve, mean attenuation was 35% at the proximal optic nerve, 52% at the distal optic nerve, 55% at the equator, and 48% at the ora serrata. Measurements at the macula (4.2 mm from the plaque edge) were highly variable, and some dose ratios were higher than The TLD localization was accurate to the nearest millimeter. However, measurements near the plaque margin are increasingly susceptible to dose variation because of inaccuracies in localization. The overall experimental error can be assessed by including the following uncertainties: (1) the SD of TLD readings is 2.5%; (2) plaque and TLD localization inaccuracy of up to 1 mm may result in measurement errors as high as 9.2% at the macula, 6.5% at the proximal optic nerve, 5.0% at the distal optic nerve, 1.6% at the equator, and 0.5% at the ora serrata; and (3) a slight tilt of the plaque may cause a significant change in the doses delivered to the points near the plaque edge such as the macula and proximal optical nerve. 890
4 Table 1. Human Ex Vivo Measurements Comparing Radiation Attenuation of 1000-Centistoke Silicone Oil vs Vitreous at Selected Points on the Surface of the Globe a Point Location 1000-cSt Silicone Oil vs Human Vitreous, Measured Dose Ratio b Globe 1 Globe 2 Globe 3 Dose Ratio, Mean (SD) Attenuation, Mean, % A Macula c c (0.50) NA B Proximal optic nerve c (0.23) 35 C Distal optic nerve Not measured (0.02) 52 D Equator (0.08) 55 E Ora serrata (0.12) 48 Abbreviations: cst, centistoke; NA, not applicable. a Ratios of doses were measured using high-sensitivity thermoluminescent dosimeters with and without 1000-cSt silicone oil substitution. b The plaque diameters were 14 mm (notched) in globe 1, 13 mm in globe 2, and 14 mm in globe 3. c Values are higher than 1.000, which may result from errors in thermoluminescent dosimeter placement or plaque tilt. Table 2. In Vitro Comparison of Radiation Attenuation by Vitreous Substitutes Relative to Saline a Solution TLD Measurement SD MC Calculation MC Calculation vs TLD, % Difference Saline NA 1000-cSt silicone oil Heavy oil NA b NA 5000-cSt silicone oil Perfluorocarbon liquid Abbreviations: cst, centistoke; MC, Monte Carlo; NA, not applicable; TLD, thermoluminescent dosimeter. a Normalized penetration factor of vitreous substitutes, 17 mm in height, from iodine 125 radiation. b The elemental composition and mass density are protected by trade secret; thus, the effective atomic number could not be calculated. Reduction Relative to Saline, % Saline 1000-cSt Silicone Oil 5000-cSt Silicone Oil Vitreous Substitute Heavy Oil In vitro Monte Carlo PFCL Table 3. Monte Carlo Modeling of Radiation Attenuation Comparing Radiation Attenuation of 1000-Centistoke Silicone Oil vs Saline at Selected Points on the Surface of the Globe a Point Location 1000-cSt Silicone Oil vs Saline, Calculated Dose Ratio Attenuation, Mean, % A Macula B Proximal optic nerve C Distal optic nerve NC NA D Equator E Ora serrata Figure 4. In vitro measurement and Monte Carlo calculation of penetration of iodine 125 ( 125 I) gamma radiation through a 17-mm depth of vitreous substitutes. cst indicates centistoke; PFCL, perfluorocarbon liquid (perfluoro-n-octane).the effective atomic number of heavy oil is protected by trade secret; theoretical penetration could not be calculated. Monte Carlo simulation of the human globe projected a dose reduction of 25% at the macula, 35% at the proximal optic nerve, 57% at the equator, and 58% at the ora serrata (Table 3). COMMENT The COMS supported the use of globe-conserving 125 I brachytherapy 3,4 ; however, nearly half of patients lose ambulatory vision (visual acuity 20/200) within 3 years. 5 An effective means of shielding the macula and optic nerve Abbreviations: cst, centistoke; NA, not applicable; NC, not calculated. a Ratios of doses were calculated at various ocular structures on a simulated globe using a Monte Carlo code with and without 1000-cSt silicone oil substitution. from collateral injury has been heretofore unproven. In this article, we have demonstrated the ability of silicone oil to significantly reduce radiation penetration. Substitution of vitreous with silicone oil at the time of plaque brachytherapy may allow for complete treatment of the tumor with reduced collateral injury and improved visual outcomes. Radiation blockade is routinely performed by radiation oncologists in other parts of the body. Radio-opaque materials (usually metal) are constructed to focus the shape of the radiation field. Unfortunately, it is extremely difficult to fixate a solid metal within the eye. Liquid metals such as mercury would be limited by toxicity. 891
5 In 1990, Finger et al 20 injected liquid iodinated contrast dyes, including iohexol and iophendylate, into rabbit eyes to block radiation. Marked attenuation of radiation occurred; however, the solubility of the dyes resulted in rapid clearance from the globe. Dye toxic effects, including intraocular inflammation and retinal degeneration, limited clinical applicability of these agents. The most notable technique in current use for the prevention of collateral injury from plaque brachytherapy is the collimated plaque developed by Astrahan et al. 21 The standard COMS gold plaque provides excellent posterior and lateral shielding in the orbit, but there is no shielding anterior to the scleral plane. By recessing the radioactive seeds into slots within the collimated plaque, side scatter is sharply reduced. This design may be particularly helpful for reducing optic nerve and macular damage in the treatment of tumors adjacent to vital structures; however, the design does not reduce the dose to structures directly across from the plaque. In this study, we performed detailed theoretical calculations and in vitro and ex vivo measurements to confirm the radiation attenuation effect of 1000-cSt silicone oil, 5000-cSt silicone oil, heavy oil, and perfluorocarbon liquid. The 1000-cSt silicone oil is a commercially available product that has the most robust attenuation effect. It has been shown to be nontoxic, nonpyrogenic, nonmutagenic, nonirritating, and readily removable, which make it an attractive tool for long-term endotamponade in vitreoretinal surgery These attributes make silicone oil attractive as a radiation-blocking substance. LIMITATIONS Clinical application of this technique requires consideration of the effect of silicone oil on the tumor as well as tolerability of the procedure. Silicone oil endotamponade should not alter the radiation dose delivered to the tumor as the oil will not be present between the tumor and the radioactive plaque. A backscatter effect from the silicone oil, which might result in increased dose to the tumor, was calculated to be negligible using Monte Carlo modeling. In the first 2 globes tested in this study, the relative radiation dose was greater than for TLD chips near the plaque edge. In globe 1, chips placed 4.2 and 7.6 mm from the plaque margin resulted in relative radiation dose ratios greater than 1.000, and in globe 2, only the chip 4.2 mm from the plaque margin showed a dose ratio greater than These findings are inconsistent with the measurements in globe 3 as well as Monte Carlo calculations. Possible causes of these findings include the effect of a notched plaque (globe 1), imprecision in TLD localization, and possible plaque edge tilt. The first globe used a notched plaque. While the notch was placed 180 from the TLDs, it is possible that some radiation was unshielded. For this reason, the notched plaque was not used for subsequent tests. Dose variability may proportionally increase with proximity to the plaque margin due to difficulty in placing and stabilizing a 3-mm square chip. Progressively meticulous attention was paid to plaque localization with each successive test. Finally, plaque tilt may significantly affect delivery of the radiation dose, resulting in reduction of the dose to the tumor apex (approximately 10%-20% for each millimeter of tilt) 27 as well as an increase of the dose to structures lateral to the tilted edge. CLINICAL APPLICATION The target dose to the tumor apex in the COMS was 85 Gy. 12,13 The optic nerve has a tolerance dose for blindness of 50 Gy 16 when irradiated with a regular high-doserate teletherapy scheme (1.8 Gy per fraction, 5 fractions per week). Based on the linear quadratic model, 28 the tolerance dose for blindness is equivalent to a dose of approximately 60 Gy with a continuous low-dose-rate irradiation for 168 hours (7 days). However, retrospective studies have demonstrated clinical evidence of optic neuropathy and maculopathy with threshold doses of 35 Gy and 21 Gy to each structure, respectively. 14,15 The potential benefit of radiation shielding may be calculated from a cohort of patients with choroidal melanoma. In a prospective study of 42 patients treated with 125 I plaque brachytherapy, 29 the median total radiation doses were 36.2 Gy (range, Gy) to the foveola and 42.8 Gy (range, Gy) to the optic nerve. Post hoc analysis of this cohort reveals that a 25% reduction of radiation to the macula would result in 21% fewer patients subjected to the 21-Gy threshold dose, while a 50% reduction in the macular dose would result in 42% fewer patients subjected to the threshold dose. A similar calculation at the optic nerve indicates that a 25% reduction in radiation to the optic nerve would result in 24% fewer patients sustaining the threshold dose of 35 Gy or higher, and a reduction by 50% would reduce this number of susceptible patients by 52%. CONCLUSIONS We have described a novel finding that silicone oil and other vitreous substitutes attenuate gamma radiation from an 125 I source. Our empirical data and theoretical calculations both demonstrate that silicone oil attenuates radiation in the human eye by as much as 55% compared with saline. In the future, this technique may be applied by performing vitrectomy and silicone oil endotamponade at the time of plaque treatment of uveal melanoma. The melanoma will still be directly irradiated using the established protocol, but radiation to other healthy ocular structures may be shielded. Vitrectomy with silicone oil endotamponade is a common and established surgical technique used in the treatment of retinal detachment, diabetic retinopathy, and macular hole. Safety and tolerability of short-term silicone oil endotamponade is well established. Future in vivo studies are required to confirm the safety and efficacy of simultaneous plaque placement, vitrectomy, and silicone oil endotamponade followed by plaque and oil removal. Attenuation of injury to vital ocular structures is calculated to reduce clinical radiation-induced complications by approximately 50%. This new technique may improve our ability to preserve vision in patients treated with plaque brachytherapy for choroidal melanoma. 892
6 Submitted for Publication: May 26, 2009; final revision received December 1, 2009; accepted January 7, Correspondence: Tara A. McCannel, MD, PhD, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Los Angeles, CA Author Contributions: Dr Oliver had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial Disclosure: None reported. Funding/Support: This work was supported by unrestricted grants from Research to Prevent Blindness, the George E. and Ruth Moss Trust, and the Frederic G. Rappaport Fellowship Award (Dr Oliver). Role of the Sponsors: The sponsors had no role in the design or conduct of the study. Additional Contributions: Bradley R. Straatsma, MD, JD, provided insightful comments on the manuscript. REFERENCES 1. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56(3): Diener-West M, Earle JD, Fine SL, et al; Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings: COMS report No. 18. Arch Ophthalmol. 2001;119(7): Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study randomized trials: COMS report No. 22. Ophthalmology. 2004;111(5): Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12): Melia BM, Abramson DH, Albert DM, et al; Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma, I: visual acuity after 3 years: COMS report No. 16. Ophthalmology. 2001;108(2): Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26(4): Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999;117(5): Boldt HC, Melia BM, Liu JC, Reynolds SM; Collaborative Ocular Melanoma Study Group. I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No ;116(1): e1. 9. Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma: analysis of the impact of time and dose factors on local control. Cancer. 1996;77(11): Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106(8): Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol. 1999;127(5): Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT; American Brachytherapy Society. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2): Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS; American Association of Physicists in Medicine. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22(2): Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation optic neuropathy. Ophthalmology. 1982;89(12): Cruess AF, Augsburger JJ, Shields JA, Donoso LA, Amsel J. Visual results following cobalt plaque radiotherapy for posterior uveal melanomas. Ophthalmology. 1984;91(2): Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1): Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3): Rivard MJ. Monte Carlo calculations of AAPM Task Group report No. 43 dosimetry parameters for the MED3631-A/M125I source. Med Phys. 2001;28(4): Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures. Springfield, VA: National Technical Information Service; Finger PT, Ho TK, Fastenberg DM, et al. Intraocular radiation blocking. Invest Ophthalmol Vis Sci. 1990;31(9): Astrahan MA, Luxton G, Pu Q, Petrovich Z. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39(2): Davis JL, Serfass MS, Lai MY, Trask DK, Azen SP. Silicone oil in repair of retinal detachments caused by necrotizing retinitis in HIV infection. Arch Ophthalmol. 1995;113(11): Brourman ND, Blumenkranz MS, Cox MS, Trese MT. Silicone oil for the treatment of severe proliferative diabetic retinopathy. Ophthalmology. 1989;96(6): Aylward GW, Cooling RJ, Leaver PK. Trauma-induced retinal detachment associated with giant retinal tears. Retina. 1993;13(2): Sell CH, McCuen BW II, Landers MB III, Machemer R. Long-term results of successful vitrectomy with silicone oil for advanced proliferative vitreoretinopathy. Am J Ophthalmol. 1987;103(1): Brinton GS, Aaberg TM, Reeser FH, Topping TM, Abrams GW. Surgical results in ocular trauma involving the posterior segment. Am J Ophthalmol. 1982; 93(3): Almony A, Breit S, Zhao H, Garcia-Ramirez J, Mansur DB, Harbour JW. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. Arch Ophthalmol. 2008;126(1): Hall EJ. Radiobiology for the Radiologist. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; Oliver SC, Young TA, Kobe LH, et al. Assessment of central vision and macular structure in patients undergoing iodine-125 brachytherapy for ciliochoroidal melanoma. Am J Clin Oncol. 2008;31(5):
Factory loaded, sterilized, ready to implant plaques:!
in partnership with Factory loaded, sterilized, ready to implant plaques: Eye Physics plaques. 2 nd generation plaques (cast in 18K gold from hand carved wax prototypes). 3 rd generation plaques (cast
More informationA REANALYSIS OF THE COLLABORATIVE OCULAR MELANOMA STUDY MEDIUM TUMOR TRIAL EYE PLAQUE DOSIMETRY
doi:10.1016/s0360-3016(03)00211-6 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 3, pp. 889 898, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front
More informationDosimetric Benefit of a New Ophthalmic Radiation Plaque
International Journal of Radiation Oncology biology physics www.redjournal.org Physics Contribution Dosimetric Benefit of a New Ophthalmic Radiation Plaque Gaurav Marwaha, MD,*,x Allan Wilkinson, PhD,*,x
More informationROPES eye plaque dosimetry: commissioning and verification of an ophthalmic brachytherapy treatment planning system
University of Wollongong Research Online Faculty of Engineering and Information Sciences - Papers: Part A Faculty of Engineering and Information Sciences 2013 ROPES eye plaque dosimetry: commissioning
More informationVisual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma
Send Orders for Reprints to reprints@benthamscience.ae The Open Ophthalmology Journal, 2015, 9, 131-135 131 Open Access Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125
More informationA practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125 I COMS plaques
Lee et al. Radiation Oncology (2018) 13:221 https://doi.org/10.1186/s13014-018-1166-z RESEARCH Open Access A practical approach to estimating optic disc dose and macula dose without treatment planning
More informationVitreoretinal surgical management In ocular oncology
www.ophtalmique.ch Vitreoretinal surgical management In ocular oncology Pournaras Jean-Antoine C Vitreoretinal Surgery Unit 1. Surgical resection after proton beam therapy 2. Ocular Biopsy 3. RD in advanced
More informationDose distribution and dosimetry parameters calculation of MED3633 palladium-103 source in water phantom using MCNP
Iran. J. Radiat. Res., 2006; 4 (1): 15-19 Dose distribution and dosimetry parameters calculation of MED3633 palladium- source in water phantom using MCNP A.A. Mowlavi 1*,A. Binesh 2, H. Moslehitabar 3
More informationAn Interactive TreatmentPlanning System For Ophthalmic Plaque Radiotherapy
An Interactive TreatmentPlanning System For Ophthalmic Plaque Radiotherapy Melvin A. Astrahan, PH.D.,¹ Gary Luxton, PH.D.,¹ Gabor Jozsef, PH.D.,¹ Thomas D. Kampp, PH.D.,¹ Peter E. Liggett, M.D.,² Michael
More informationSeed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 6, 2015 Seed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge Sarah E. McCauley Cutsinger, 1a Keith M. Furutani, 1
More informationComparison of dosimetry parameters of two commercially available Iodine brachytherapy seeds using Monte Carlo calculations
Iran. J. Radiat. Res., 21; 7 (4): 217-222 Comparison of dosimetry parameters of two commercially available Iodine brachytherapy seeds using Monte Carlo calculations Downloaded from ijrr.com at 6:52 +33
More informationResearch Article Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience
ISRN Ophthalmology, Article ID 95975, 7 pages http://dx.doi.org/1.1155/214/95975 Research Article Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional
More informationMonte Carlo simulation of 192 Ir radioactive source in a phantom designed for brachytherapy dosimetry and source position evaluation.
Monte Carlo simulation of 192 Ir radioactive source in a phantom designed for brachytherapy dosimetry and source position evaluation Samuel Chiquita 1 1 University of Porto, Porto, Portugal Abstract In
More informationMethod for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 15, NUMBER 4, 2014 Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma L. W. Zimmermann, 1a D. Allan Wilkinson
More informationTransvitreal Fine Needle Aspiration Biopsy of Choroidal Melanoma via Pars Plana Vitrectomy
Surgical Technique Is pars plana vitrectomy a safe method for performing fine needle aspiration biopsy of choroidal melanoma? What are the rates of complications? Clinical Characteristics Do tumor thickness
More informationDosimetric characteristics of 137 Cs sources used in after loading Selectron system by Monte Carlo method
Iran. J. Radiat. Res., 2007; 5 (3): 147-152 Dosimetric characteristics of Cs sources used in after loading Selectron system by Monte Carlo method M.B.Tavakoli, D. Shahbazi-Gahrouei *, M. Hosseinpour Department
More informationIntraoperative Visualization of Peripheral Retina with Wide-Angle Viewing Systems
Intraoperative Visualization of Peripheral Retina with Wide-Angle Viewing Systems Homayoun Tabandeh, M.D., MS, Francesco Boscia, M.D. 1. Retina -Vitreous Associates Medical Group, Los Angeles, California,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationCan Protons replace Eye Brachytherapy? 1 Department of Radiation Oncology
Can Protons replace Eye Brachytherapy? Richard Pötter 1,2, Roman Dunavölgyi 3, Karin Dieckmann 1, Dietmar Georg 1,2 1 Department of Radiation Oncology 2 Christian Doppler Laboratory for Medical Radiation
More informationCoagulative necrosis in a malignant melanoma of the choroid at the macula with extensive subretinal hemorrhage
Coagulative necrosis in a malignant melanoma of the choroid at the macula with extensive subretinal hemorrhage Robert D. Yee, Robert Y. Foos, and Bradley R. Straatsma The authors present a case report
More informationProgressive Symptomatic Retinal Detachment Complicating Retinoschisis. Initial Reporting Questionnaire
Progressive Symptomatic Retinal Detachment Complicating Retinoschisis In association with the British Ophthalmological Surveillance Unit Ethics ref: 13/NW/0037 Initial Reporting Questionnaire Case Definition:
More informationEpiscleral plaque brachytherapy has been proposed as an
Effect of Radiation Dose on Ocular Complications after Iodine Brachytherapy for Large Uveal Melanoma: Empirical Data and Simulation of Collimating Plaques Ilkka Puusaari, 1 Jorma Heikkonen, 2 and Tero
More informationManik Aima, Larry A. DeWerd, Wesley S. Culberson
Manik Aima, Larry A. DeWerd, Wesley S. Culberson University of Wisconsin Medical Radiation Research Center, Madison, WI 25 th Annual Meeting of the Council of Ionizing Radiation Measurements and Standards,
More informationInherent precision. Ru-106 Eye Applicators and I-125 Ophthalmic Seeds.
Inherent precision Ru-106 Eye Applicators and I-125 Ophthalmic Seeds www.bebig.com Brachytherapy for Eye Tumors Ophthalmic Brachytherapy The treatment of ocular tumors is selected according to the size
More informationProton Radiation Therapy of Ocular Melanoma at PSI
Proton Radiation Therapy of Ocular Melanoma at PSI G. Goitein*, A. Schalenbourg, J. Verwey*, A. Bolsi*, C. Ares*, L. Chamot, E. Hug*, L. Zografos *Paul Scherrer Institut, 5232 Villigen PSI; Hôpital Ophtalmique,
More informationIntraoperative biometry for intraocular lens (IOL) power calculation at silicone oil removal
European Journal of Ophthalmology / Vol. 13 no. 7, 2003 / pp. 622-626 Intraoperative biometry for intraocular lens (IOL) power calculation at silicone oil removal S.M. EL-BAHA, A. EI-SAMADONI, H.F. IDRIS,
More informationEpiscleral eye plaque dosimetry comparison for the Eye Physics EP917 using Plaque Simulator and Monte Carlo simulation
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 6, 2015 Episcleral eye plaque dosimetry comparison for the Eye Physics EP917 using Plaque Simulator and Monte Carlo simulation Leonard W.
More informationRoyal Berkshire Hospital Dunedin Hospital. Prince Charles Eye Unit Pi Princess Margaret Hospital
Vitreoretinal Surgery Mr Vaughan Tanner www.tanner-eyes.co.uk eyes Reading Royal Berkshire Hospital Dunedin Hospital Windsor Prince Charles Eye Unit Pi Princess Margaret Hospital Success rates VR surgery
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationRetina Center of Oklahoma Sam S. Dahr, M.D. Adult Intraocular Tumors
Adult Intraocular Tumors Sam S. Dahr, M.D. Retina Center of Oklahoma www.retinacenteroklahoma.com www.rcoklahoma.com Table of Contents Posterior uveal malignant melanoma Uveal metastasis Uveal melanoma
More informationApplication of MCNP4C Monte Carlo code in radiation dosimetry in heterogeneous phantom
Iran. J. Radiat. Res., 2003; 1(3): 143-149 Application of MCNP4C Monte Carlo code in radiation dosimetry in heterogeneous phantom A. Mostaar 1, M. Allahverdi 1,2, M. Shahriari 3 1 Medical Physics Department,
More informationJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationCLINICAL SCIENCES. Pretreatment Characteristics and Response to Plaque Radiation Therapy
CLINICAL SCIENCES Subfoveal Choroidal Melanoma Pretreatment Characteristics and Response to Plaque Radiation Therapy Hadas Newman, MD; Kimberly J. Chin, OD; Paul T. Finger, MD Objective: To evaluate the
More informationNote: This is an outcome measure and can be calculated solely using registry data.
Measure #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery -- National Quality Strategy Domain: Effective Clinical Care DESCRIPTION: Percentage of patients
More informationAnatomical results and complications after silicone oil removal
Romanian Journal of Ophthalmology, Volume 61, Issue 4, October-December 2017. pp:261-266 GENERAL ARTICLE Anatomical results and complications after silicone oil removal Brănişteanu Daniel Constantin* **,
More informationOptimisation of eye plaque dosimetry using Monte Carlo method. J. Green, D. Cutajar, S. Guatelli, & Rosenfeld, A.B.
Optimisation of eye plaque dosimetry using Monte Carlo method J. Green, D. Cutajar, S. Guatelli, & Rosenfeld, A.B. Cancer of the eye is a rare and challenging disease Uveal melanoma is the most prevalent
More informationReview of TG-186 recommendations
Review of TG-186 recommendations Implementation of advanced brachytherapy dose calculation algorithms beyond TG-43 Rowan M. Thomson Carleton Laboratory for Radiotherapy Physics Carleton University Ottawa
More informationMeasure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery 2012 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: Percentage
More informationQuantitative OCT Angiography Evaluation of Peripapillary Retinal Circulation after Plaque Brachytherapy
Quantitative OCT Angiography Evaluation of Peripapillary Retinal Circulation after Plaque Brachytherapy Alison H. Skalet, MD, PhD, 1,2, * Liang Liu, MD, 1, * Christina Binder, MD, PhD, 2 Audra K. Miller,
More informationRisk of a second cancer after radiotherapy
Risk of a second cancer after radiotherapy Francesco d Errico University of Pisa, Italy Yale University, USA Medical radiological procedures worldwide 2.5 billion diagnostic radiological examinations 78%
More informationNOVEL SOFTWARE MODULES FOR TREATMENT PLANNING OF 106 RU EYE PLAQUE BRACHYTHERAPY
NOVEL SOFTWARE MODULES FOR TREATMENT PLANNING OF 106 RU EYE PLAQUE BRACHYTHERAPY Gerd Heilemann, Lukas Fetty, Matthias Blaickner, Nicole Nesvacil, R. Dunavölgyi, and Dietmar Georg ESTRO 35 Forum 29 April
More information1.1 Terminology of Mechanical Injuries: the Birmingham Eye Trauma Terminology (BETT)
1.1 Terminology of Mechanical Injuries: the Birmingham Eye Trauma Terminology (BETT) Ferenc Kuhn, Robert Morris, Viktória Mester, C. Douglas Witherspoon 1.1.1 If the Terminology Is Not Standardized Akin
More informationSudden Vision Loss. Brendan Girschek, MD, FRCSC, FACS Vitreoretinal Surgery Cedar Valley Medical Specialists
Sudden Vision Loss Brendan Girschek, MD, FRCSC, FACS Vitreoretinal Surgery Cedar Valley Medical Specialists My Credentials -Residency in Ophthalmology at the LSU Eye Center in New Orleans, LA -Fellowship
More informationLaser pointer phototoxicity. Antonio Ciardella Bologna, Italy
Laser pointer phototoxicity Antonio Ciardella Bologna, Italy Handheld Green Laser-Pointer Maculopathy (HLPM) Laser pointer class 3 B can cause permanent eye damage with exposures of 1/100 th of a second
More informationAcute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient
CM&R Rapid Release. Published online ahead of print September 20, 2012 as Aperture Acute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient Elizabeth
More informationTLD as a tool for remote verification of output for radiotherapy beams: 25 years of experience
IAEA-CN-96-82 TLD as a tool for remote verification of output for radiotherapy beams: 25 years of experience J. Francisco Aguirre, Ramesh C. Tailor, Geoffrey S. Ibbott, Marilyn Stovall and William F. Hanson
More informationCarlo Mosci. Ocular Oncology Service Galliera Hospital Genova Italy (www.galliera.it)
RADIATION INDUCED Carlo Mosci Ocular Oncology Service Galliera Hospital Genova Italy (www.galliera.it) "Working Day - Radiation Side Effects" carlo.mosci@galliera.it RADIATION INDUCED Different treatment
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management
More informationOphthalmic tumors. Wolfgang Sauerwein
Ophthalmic tumors Wolfgang Sauerwein Today s menu Introduction and some basics on uveal melanoma Brachytherapy for intraocular tumors Proton therapy for intraocular tumors Proton therapy for conjunctival
More informationUniversity of Wollongong. Research Online
University of Wollongong Research Online Faculty of Engineering and Information Sciences - Papers: Part A Faculty of Engineering and Information Sciences 2013 I-125 ROPES eye plaque dosimetry: Validation
More informationVenturi versus peristaltic pumps 33 vitrectomy dynamics 34 Fluorescein, vitreous staining 120
Subject Index Accurus 35, 83 Aflibercept, diabetic macular edema management 167, 168 Air-forced infusion, Stellaris PC 12, 13 Alcon Constellation, see Constellation system Autoclave sterilization lens
More informationLate-onset Retinal Detachment Associated with Regressed Retinopathy of Prematurity
Late-onset Retinal Detachment Associated with Regressed Retinopathy of Prematurity Hiroko Terasaki*, and Tatsuo Hirose* *Schepens Retina Associates, Schepens Eye Research Institute, Harvard Medical School,
More informationAAPM Administrative Policy: Joint AAPM/IROC Houston Registry of Brachytherapy Sources Complying with AAPM Dosimetric Prerequisites
AAPM Administrative Policy: Joint AAPM/IROC Houston Registry of Brachytherapy Sources Complying with AAPM Dosimetric Prerequisites A. Purpose and Rationale Many individual users contact the AAPM Brachytherapy
More informationSURGICAL VITREORETINAL FELLOWSHIP PROGRAM. UNIVERSITY OF KENTUCKY AND RETINA ASSOCIATES OF KENTUCKY Lexington, Kentucky
SURGICAL VITREORETINAL FELLOWSHIP PROGRAM UNIVERSITY OF KENTUCKY AND RETINA ASSOCIATES OF KENTUCKY Lexington, Kentucky UK Fellowship Director P. Andrew Pearson, M.D. UK Vitreoretinal Faculty Romulo Albuquerque,
More informationCase Rep Oncol 2012;5: DOI: /
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationSpinal Cord Doses in Palliative Lung Radiotherapy Schedules
Journal of the Egyptian Nat. Cancer Inst., Vol. 8, No., June: -, 00 Spinal Cord Doses in Palliative Lung Radiotherapy Schedules HODA AL-BOOZ, FRCR FFRRCSI M.D.* and CAROL PARTON, Ph.D.** The Departments
More informationProtection of the contralateral breast during radiation therapy for breast cancer
Protection of the contralateral breast during radiation therapy for breast cancer Edgardo Garrigó a*, Alejandro Germanier b, Silvia Zunino a a Instituto Privado de Radioterapia, Ob Oro 423 (5000) Córdoba,
More informationAn anthropomorphic head phantom with a BANG polymer gel insert for dosimetric evaluation of IMRT treatment delivery
An anthropomorphic head phantom with a BANG polymer gel insert for dosimetric evaluation of IMRT treatment delivery G. Ibbott a, M. Beach a, M. Maryanski b a M.D. Anderson Cancer Center, Houston, Texas,
More informationDiode calibration for dose determination in total body irradiation
Iran. J. Radiat. Res., 2008; 6 (1): 43-50 Diode calibration for dose determination in total body irradiation M.Allahverdi 1*, Gh. Geraily 1, M. Esfehani 3,A. Sharafi 2,A. Shirazi 1 1 Department of Medical
More informationRecurrences of retinal detachment after vitreoretinal surgery, and surgical approach
European Journal of Ophthalmology / Vol. 11 n. 2, 2001 / pp. 166-170 Recurrences of retinal detachment after vitreoretinal surgery, and surgical approach Z. KAPRAN 1, O.M. UYAR 1, V. KAYA 2, K. ELTUTAR
More informationRadiochromic film dosimetry in water phantoms
INSTITUTE OF PHYSICS PUBLISHING PHYSICS IN MEDICINE AND BIOLOGY Phys. Med. Biol. 46 (2001) N27 N31 www.iop.org/journals/pb PII: S0031-9155(01)16858-2 NOTE Radiochromic film dosimetry in water phantoms
More informationDosimetric characterization of surface applicators for use with the Xoft ebx system
Dosimetric characterization of surface applicators for use with the Xoft ebx system R.M. Kennedy University of Wisconsin Medical Research Center Madison, WI April 23, 2010 Introduction Squamous and basal
More informationOnline in vivo dosimetry in conformal radiotherapies with MOSkin detectors
Online in vivo dosimetry in conformal radiotherapies with MOSkin detectors G.Gambarini 1, C.Tenconi 1, N.Mantaut 1 M.Carrara 2, M.Borroni 2, E.Pignoli 2 D.Cutajar 3, M.Petasecca 3, I.Fuduli 3, M.Lerch
More informationChoroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk cases
European Journal of Ophthalmology / Vol. 14 no. 4, 2004 / pp. 325-329 Choroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk
More informationManagement and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan
Original Article doi:./tjpath.. Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan Ahmed Zewar, Ibrahim Nawaiseh, Imad Jaradat, Jakub Khzouz, Khaleel AlRawashdeh, Ghadeer
More informationThe Foundation. RETINA HEALTH SERIES Facts from the ASRS
Complex Retinal Detachment: Proliferative Vitreoretinopathy and Giant Retinal Tears Proliferative vitreoretinopathy (PVR) is a condition in which retinal scar tissue, or membranes form; this may occur
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationSystemic and ocular follow-up after conservative management of an intraocular tumor
Systemic and ocular follow-up after conservative management of an intraocular tumor 7 th Thessaloniki international Vitreo Retinal Summer School,26.6-1.7.2017 L. Zografos MD Jules Gonin Eye Hospital Periodic
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationTall, dark and.. Uh oh
Tall, dark and.. Uh oh Jesse L. Berry, MD Arizona Ophthalmology Society 2017 Ocular Oncology Service USC Eye Institute Financial Disclosures Research Support: Bright Eyes Nautica Foundation Knights Templar
More informationTiffany L. Kruger, D.O. Children s Hospital of Michigan Wayne State University/Kresge Eye Institute
Pediatric Cases Nt Not To Be Missed Tiffany L. Kruger, D.O. Pediatric Ophthalmology Fellow Children s Hospital of Michigan Wayne State University/Kresge Eye Institute Case Presentation CC: Left eye turns
More informationNote: This is an outcome measure and will be calculated solely using registry data.
Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
More informationPatient dosimetry for total body irradiation using single-use MOSFET detectors
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 9, NUMBER 4, FALL 2008 Patient dosimetry for total body irradiation using single-use MOSFET detectors Tina Marie Briere, 1 Ramesh Tailor, 1 Naresh Tolani,
More informationDose to professionals in epiescleral brachytherapy
Dose to professionals in epiescleral brachytherapy De Frutos-Baraja JM, del Castillo-Belmonte A, Hernando-González I, Sánchez-Carmona G, Cid-Galache A, Barrio-Lazo FJ, Pereda-Barroeta N, Giraldo-Arguello
More informationNational Guidelines for the management of uveal melanoma. Sponsored by Melanoma Focus
National Guidelines for the management of uveal melanoma Sponsored by Melanoma Focus GDG Members Paul Nathan (Chair Oncologist Mt Vernon) Kieran McGuirk (Ocumel) Lesley Kirkpatrick (Ocumel) Kathryn Curtis
More informationat the Leading Edge Cannulas 20 & 23 Gauge Instruments Vitreoretinal
E s ta bl is h ed i n 19 59 20 & Instruments 20g 23g Vitreoretinal 23g 25g Cannulas Re-usable Titanium Cannulas Enhanced performance with better fixation and stabilisation compared to single use 7 Marquis
More informationInsertion of an epiretinal prosthesis for retinitis pigmentosa
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Insertion of an epiretinal prosthesis for retinitis pigmentosa Retinitis pigmentosa is a disease that affects
More informationAbsorbed Dose Response in Water of Kilovoltage X-rays Beams of Radiochromic Film and Thermoluminescent for Brachytherapy Dosimetry
Absorbed Dose Response in Water of Kilovoltage X-rays Beams of Radiochromic Film and Thermoluminescent for Brachytherapy Dosimetry Chien-Hau Chu 1, Uei-Tyng Lin 1, Ngot-Swan Chong 2, Wen-Song Hwang 1,
More informationExtracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 2, SPRING 2006 Extracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas Thomas Samuel Ram, a Paul B. Ravindran,
More informationA Little Physics. How Does It Work? Radiation Therapy for Choroidal Neovascularisation in AMD A Review. => cell death
Radiation Therapy for Choroidal Neovascularisation in AMD A Review Jen Anikina ST4 Hillingdon Hospital A Little Physics One gray is the absorption of one joule of ionizing radiation energy per kilogram
More informationComparison Between 20- Gauge And 23-Gauge Vitrectomy In Diabetic Patients
Asok Nataraj MS Abstract Aim: - Comparison Between 20- Gauge And 23-Gauge Vitrectomy In Diabetic Patients The purpose of this study was to directly compare the outcome, safety and efficacy of the 20G and
More informationCLINICAL SCIENCES. Conclusions: A distinctive postbrachytherapy regression
horoidal Melanomas With a ollar-utton onfiguration Response Pattern fter Iodine 125 rachytherapy Dennis M. Robertson, MD LINIL SIENES Objective: To describe a distinctive type of postbrachytherapy response
More informationImplantation of a corneal graft keratoprosthesis for severe corneal opacity in wet blinking eyes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Implantation of a corneal graft keratoprosthesis for severe corneal opacity in wet blinking eyes The cornea
More informationScleral buckling. Surgical Treatment
Dr. Ayman M. Khattab MD, FRCS professor of Ophthalmology Cairo University Surgical Treatment Pneumatic retinopexy. Primary pars plana vitrectomy. 1 Indications for scleral buckling. SB is used to treat
More informationAssessment of variation of wedge factor with depth, field size and SSD for Neptun 10PC Linac in Mashhad Imam Reza Hospital
Iran. J. Radiat. Res., 2004; 2 (2): 53-58 Assessment of variation of wedge factor with depth, field size and SSD for Neptun 10PC Linac in Mashhad Imam Reza Hospital M. Hajizadeh Saffar 1*, M.R. Ghavamnasiri
More informationUveal Melanoma. Protocol applies to malignant melanoma of the uvea.
Uveal Melanoma Protocol applies to malignant melanoma of the uvea. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist) Biopsy (No Accompanying
More informationResearch Article Dose Distributions of an 192 Ir Brachytherapy Source in Different Media
BioMed Research International, Article ID 946213, 11 pages http://dx.doi.org/10.1155/2014/946213 Research Article Dose Distributions of an 192 Ir Brachytherapy Source in Different Media C. H. Wu, 1 Y.
More informationOcular Trauma: Principles and Practice
Ocular Trauma: Principles and Practice von Dante J. Pieramici Ferenc Kuhn 1. Auflage Thieme 2002 Verlag C.H. Beck im Internet: www.beck.de ISBN 978 3 13 125771 0 Zu Leseprobe schnell und portofrei erhältlich
More informationCyberknife Radiosurgery for Uveal Melanoma
Cyberknife Radiosurgery for Uveal Melanoma Kirsten Eibl, Alexander Muacevic, Anselm Kampik Cyberknife Center Munich-Großhadern in cooperation with the University Hospital of the University Munich Uveal
More informationI t is possible to apply large doses of
Proton irradiation of simulated ocular tumors Ian J. Constable, Andreas M. Koehler, and Robert A. Schmidt Silicone sponges were sutured to the sclera of owl monkeys to create an indentation which would
More informationVanderbilt Eye Institute Clinical Trials
April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director
More informationVitrectomy for Diabetic Cystoid Macular Edema
Vitrectomy for Diabetic Cystoid Macular Edema Yukihiro Sato, Zeon Lee and Hiroyuki Shimada Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan Purpose: We evaluated visual outcomes
More informationRETINAL DETACHMENT AT THE POSTERIOR POLE*
Brit. J. Ophthal. (1958) 42, 749. RETINAL DETACHMENT AT THE POSTERIOR POLE* BY CALBERT I. PHILLIPSt Institute of Ophthalmology, University oflondon THE common feature of the cases to be described in this
More informationEye plaque dosimetry verification using novel solid state devices
University of Wollongong Research Online University of Wollongong Thesis Collection University of Wollongong Thesis Collections 2014 Eye plaque dosimetry verification using novel solid state devices Talia
More informationThree-dimensional dosimetry imaging of I-125 plaque for eye cancer treatment
University of Wollongong Research Online Sydney Business School - Papers Faculty of Business 2011 Three-dimensional dosimetry imaging of I-125 plaque for eye cancer treatment Michael Weaver University
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 6.01.10 Stereotactic Radiosurgery and Stereotactic Body Radiotherapy 8.01.10 Charged-Particle (Proton
More informationMETHODS FOR coding the
Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS) COMS Report No. 15 The Collaborative Ocular Melanoma Study
More informationStandard calibration of ionization chambers used in radiation therapy dosimetry and evaluation of uncertainties
Standard calibration of ionization chambers used in radiation therapy dosimetry and evaluation of uncertainties A. Solimanian and M. Ghafoori * Iran. J. Radiat. Res., 2010; 8 (3): 195-199 Radiation Dosimetry
More informationICO-Ophthalmology Surgical Competence Assessment Rubric Vitrectomy (ICO-OSCAR:VIT)
ICO-Ophthalmology Surgical Competence Assessment Rubric Vitrectomy (ICO-OSCAR:VIT) Date Resident Evaluator Novice (score = 2) Beginner (score = 3) Advanced Beginner (score = 4) Competent (score = 5) Not
More information